ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Dec 26, 2014
HCV Competition Not New “News” for Gilead
Gilead is trading more than 40% above its 52-week low and about 20% from its 52-week high. We see no reason to panic, and the company’s trading activity more closely reflects a company whose stock price has quintupled in recent years than one that is in any trouble whatsoever. Gilead’s shares bounced right off technical support levels, and we see a long term that is still very bright for the biotech. Gilead’s shares remain underpriced even under a bear-case scenario.
Nov 29, 2014
$45 Oil Prices!?!? There Is Never a Sense of Urgency When One Is Prepared
Friday brought mass selling across the energy sector. In our view, crude oil prices could hit $45 per barrel in the next few years before recovering.
Oct 29, 2014
Gilead’s Revenue More Than Doubles in Third Quarter
Antiviral sales at the company remain strong, and we continue to like opportunities in its pipeline.
Oct 15, 2014
Johnson & Johnson: Still a Solid Dividend Growth Pick
We have no plans to remove Johnson & Johnson from the Dividend Growth portfolio.
Oct 10, 2014
The Correction: Draghi; Chip, Telecom Warnings; Oil and MLPs
“Without reform, there can be no recovery.” – European Central Bank President Mario Draghi
Sep 1, 2014
This Firm Just Registered a 10 on the Valuentum Buying Index
This firm's new treatment has a high rate of effectiveness, and its lack of competition has fueled rapid adoption in the medical community. This firm has so much monopolistic power that Congress is complaining that it is putting too much budgetary pressure on Medicare and Medicaid. The company just registered the highest rating of a 10 on the Valuentum Buying Index (equivalent to a "we'd consider buying" rating), and we think there is considerable share-price upside. The stock not only trades at a material discount to its discounted cash-flow-derived intrinsic value, but its earnings multiple is but a fraction of its peer group's.
Aug 9, 2014
Energy Transfer Partners’ Solid Distribution Coverage Ratio
Energy Transfer Partners’ distribution is on solid ground, but investors should be aware of the risks of MLPs. Let’s walk through a quick reminder.
Jul 30, 2014
Big Pharma Round Up
Let’s take a look at recent quarterly results from Big Pharma.
Jul 16, 2014
Johnson & Johnson: Beat and Raise
We like this dividend growth giant quite a bit.
Jun 9, 2014
The M&A Environment Remains Robust
Let’s take a look at a few deals that hit the wires recently – some proposed, some speculated.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.